Bevacizumab is an Efficient Therapeutic Approach with Low Side Effects in Patient-Derived Xenografts of Adenoid Cystic Carcinoma of the Lacrimal Gland

PURPOSE: Adenoid cystic carcinoma (ACC) of the lacrimal gland (LGACC) is an aggressive malignant lacrimal gland tumor with a generally poor prognosis. Survival rates for LGACC are 56% at 5 years and 49% at 10 years. Recent studies have indicated that anti-vascular endothelial growth factor (VEGF) th...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jingxue, Yan, Xuejing, Liu, Rui, Wu, Shen, Liu, Qian, Li, Jing, Ma, Jianmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8912937/
https://www.ncbi.nlm.nih.gov/pubmed/35283648
http://dx.doi.org/10.2147/CMAR.S352623

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8912937/
https://www.ncbi.nlm.nih.gov/pubmed/35283648
http://dx.doi.org/10.2147/CMAR.S352623

Ejemplares similares